Literature DB >> 16241947

A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis.

N Komanasin1, A J Catto, T S Futers, A van Hylckama Vlieg, F R Rosendaal, R A S Ariëns.   

Abstract

BACKGROUND: Factor (F)XIII B-subunit, which plays a carrier role for zymogen FXIIIA, is highly polymorphic, but the molecular basis for these polymorphisms and their relationship to disease remains unknown.
OBJECTIVES: To screen the FXIIIB gene coding region for common variation and analyze possible functional effects. METHODS AND
RESULTS: We examined the FXIIIB gene by PCR-SSCP and identified three common single nucleotide polymorphisms: A8259G, C29470T and A30899G. A8259G results in substitution of His95Arg in the second Sushi domain. An FXIII tetramer ELISA was developed to analyze B-subunit dissociation from A-subunit (leading to access to the catalytic site of FXIII). Increased subunit dissociation, 0.51 vs. 0.45 (fraction of total tetramer), was found in plasma from subjects possessing the Arg-allele. However, when the variants were purified to homogeneity and binding was analyzed by steady-state kinetics, no difference was observed. The relationship between His95Arg and venous thrombosis was investigated in 214 patients and 291 controls from Leeds. His/Arg + Arg/Arg genotypes were more frequent in patients than controls (22.4% vs. 15.1%). His95Arg was also investigated in the Leiden Thrombophilia Study, in which a similar difference was observed for 471 patients vs. 472 controls (18.5% vs. 14.0%), for a pooled odds ratio (OR) of 1.5 (CI95 1.1-2.0).
CONCLUSIONS: We have identified three FXIIIB polymorphisms, one of which codes for substitution of His95Arg. The Arg95 variant associates with a moderately increased risk for venous thrombosis, and with increased dissociation of the FXIII subunits in plasma, although in vitro steady-state binding between purified subunits was not affected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16241947     DOI: 10.1111/j.1538-7836.2005.01624.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  16 in total

1.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

2.  A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.

Authors:  Weihong Tang; Martina Teichert; Daniel I Chasman; John A Heit; Pierre-Emmanuel Morange; Guo Li; Bruno H Ch Stricker; Paul M Ridker; Aaron R Folsom; Nicholas L Smith; Nathan Pankratz; Frank W Leebeek; Guillaume Paré; Mariza de Andrade; Christophe Tzourio; Bruce M Psaty; Saonli Basu; Rikje Ruiter; Lynda Rose; Sebastian M Armasu; Thomas Lumley; Susan R Heckbert; André G Uitterlinden; Mark Lathrop; Kenneth M Rice; Mary Cushman; Albert Hofman; Jean-Charles Lambert; Nicole L Glazer; James S Pankow; Jacqueline C Witteman; Philippe Amouyel; Joshua C Bis; Edwin G Bovill; Xiaoxiao Kong; Russell P Tracy; Eric Boerwinkle; Jerome I Rotter; David-Alexandre Trégouët; Daan W Loth
Journal:  Genet Epidemiol       Date:  2013-05-05       Impact factor: 2.135

Review 3.  Newly-Recognized Roles of Factor XIII in Thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

4.  Plasma factor XIII: understanding the 99%.

Authors:  Alisa S Wolberg
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

5.  Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin.

Authors:  D M O Pruissen; F R Rosendaal; J W Gorter; A A Garcia; L J Kappelle; A Algra
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

6.  Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology.

Authors:  Mary Cushman; Ellen S O'Meara; Aaron R Folsom; Susan R Heckbert
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113

7.  Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.

Authors:  László Balogh; Éva Katona; Zoltán A Mezei; Judit Kállai; Réka Gindele; István Édes; László Muszbek; Zoltán Papp; Zsuzsanna Bereczky
Journal:  Mol Cell Biochem       Date:  2018-02-26       Impact factor: 3.396

8.  Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients.

Authors:  Donato Gemmati; Federica Federici; Gianluca Campo; Silvia Tognazzo; Maria L Serino; Monica De Mattei; Marco Valgimigli; Patrizia Malagutti; Gabriele Guardigli; Paolo Ferraresi; Francesco Bernardi; Roberto Ferrari; Gian L Scapoli; Linda Catozzi
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

9.  Natural selection and the molecular basis of electrophoretic variation at the coagulation F13B locus.

Authors:  Anthony W Ryan; David A Hughes; Kun Tang; Dermot P Kelleher; Thomas Ryan; Ross McManus; Mark Stoneking
Journal:  Eur J Hum Genet       Date:  2008-08-20       Impact factor: 4.246

10.  Genes influencing coagulation and the risk of aneurysmal subarachnoid hemorrhage, and subsequent complications of secondary cerebral ischemia and rebleeding.

Authors:  Ynte M Ruigrok; Arjen J C Slooter; Gabriel J E Rinkel; Cisca Wijmenga; Frits R Rosendaal
Journal:  Acta Neurochir (Wien)       Date:  2009-10-14       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.